Sutro Biopharma was once worth $1 billion, another Bay Area biotech company with deep coffers and a novel research plan. And now, like at so many of its peers, the layoffs are stacking up.
After cutting about half of its staff in March, Sutro revealed plans on Monday to lay off about a third of its remaining workers. The company, which designs cancer treatments called antibody-drug conjugates, announced the new layoffs in a filing with the Securities and Exmodify Commission, writing that its restructuring effort would extconclude its cash runway into mid-2027.
A day later, workers started obtainting their pink slips. A WARN filing from Sutro, delivered to California officials and obtained by SFGATE, declares the layoffs would launch on Tuesday and include eight workers in San Carlos, one remote employee and 45 at the company’s headquarters in South San Francisco.
Most of the layoffs are hitting workers in scientist, researcher and engineer roles, per the WARN, but a few directors of various types are also losing their jobs. As with the company’s layoff round from March, the cuts will be staggered, this time through mid-December.
That earlier layoff round, as SFGATE reported at the time, came as Sutro shut down a manufacturing facility and “deprioritized” its investment in its only drug candidate that had reached clinical trials. It also swapped out its CEO, chief financial officer and chief medical officer.
Sutro now has three antibody-drug conjugates in the works — these treatments are designed to tarobtain specific cancer cells, sparing the healthy cells around them. CEO Jane Chung, in a Monday news release, wrote that the company is on track to obtain one of those treatments into clinical trials this year. The layoffs, or “operational efficiencies,” as she alluded to them, serve the goal of keeping the company alive until at least that trial data comes in, and another trial can kick off.
Chung wrote: “Importantly, these modifys extconclude our expected financial runway through critical milestones and strengthen our ability to create value for both patients and shareholders. We are deeply grateful to the dedicated employees who have contributed to Sutro’s progress, and their work will remain foundational to our mission shifting forward.”
Sutro is in a precarious spot. Investors have all but ditched the company, currently valuing it at $78 million — less than the $205 million Sutro had available at the conclude of June, per a filing. And as Fierce Biotech reported in August, Sutro lost a potentially lucrative development deal when its partner company, Ipsen, pulled out.
The company declined to provide SFGATE with additional comment.
Work at a Bay Area tech company and want to talk? Contact tech reporter Stephen Council securely at stephen.council@sfgate.com or on Signal at 628-204-5452.
Leave a Reply